比索洛尔与维拉帕米在非梗阻性肥厚型心肌病中的随机三交叉生理学试验
结果显示比索洛尔降低pVO2,而维拉帕米不降低pVO2;两药在运动反应、结构、心肌功能、症状和生物标志物方面存在显著差异。
要点
- 比索洛尔降低非梗阻性HCM患者的峰值耗氧量,维拉帕米则未降低。
- 维拉帕米改善整体纵向应变并降低NT-proBNP,比索洛尔则升高NT-proBNP和左房容积指数。
- 比索洛尔降低KCCQ总分并增加三尖瓣反流压差,维拉帕米未引起这些变化。
核心结论
- 在非梗阻性HCM中,比索洛尔治疗降低峰值耗氧量,而维拉帕米治疗未改变峰值耗氧量。
- 两药在运动反应、结构改变、心肌功能、症状和生物标志物方面存在多项显著差异。
研究设计与样本
- 入选标准包括至少一项疾病严重度标志:NYHA功能分级≥II、NT-proBNP>300 ng/L或记录到非持续性室性心动过速。
- 每位患者接受三个治疗期,目标剂量分别为比索洛尔7.5 mg、维拉帕米360 mg和安慰剂,稳态治疗2周后评估结局。
- 主要结局为峰值耗氧量(pVO2)。
主要发现
- pVO2在比索洛尔组为25.7±8.7 mL/kg/min,维拉帕米组为28.2±8.6 mL/kg/min,安慰剂组为28.7±8.7 mL/kg/min。
- 校正后平均差值:比索洛尔 vs 维拉帕米为-1.8 mL/kg/min(P=0.013),比索洛尔 vs 安慰剂为-2.5 mL/kg/min(P=0.002),维拉帕米 vs 安慰剂为-0.7 mL/kg/min(P=0.990)。
- 与安慰剂相比,比索洛尔降低峰值心率(-37次/分;P<0.001),维拉帕米降低峰值心率(-17次/分;P<0.001)。
- 与安慰剂相比,维拉帕米改善整体纵向应变(-1.1%;P=0.001),比索洛尔未改变整体纵向应变(-0.6%;P=0.263)。
- 与安慰剂相比,比索洛尔降低KCCQ总分(-6.6分;P=0.001)、升高NT-proBNP(+165 ng/L;P=0.006)、增加左房容积指数(+13.0 mL/m2;P<0.001)和三尖瓣反流压差(+4.3 mm Hg;P=0.049);维拉帕米未改变KCCQ总分(-2.3分;P=0.668)、左房容积指数(+5.2 mL/m2;P=0.194)和三尖瓣反流压差(+1.1 mm Hg;P=1.000),但降低NT-proBNP(-177 ng/L;P<0.001)。
关键数值与推荐
- 非梗阻性HCM患者中,比索洛尔目标剂量7.5 mg、维拉帕米目标剂量360 mg,稳态治疗2周后评估。
- 主要结局pVO2的组间校正平均差值:比索洛尔 vs 维拉帕米-1.8 mL/kg/min(P=0.013),比索洛尔 vs 安慰剂-2.5 mL/kg/min(P=0.002),维拉帕米 vs 安慰剂-0.7 mL/kg/min(P=0.990)。
- 与安慰剂相比,比索洛尔降低KCCQ总分6.6分(P=0.001),升高NT-proBNP 165 ng/L(P=0.006),增加左房容积指数13.0 mL/m2(P<0.001),增加三尖瓣反流压差4.3 mm Hg(P=0.049)。
- 与安慰剂相比,维拉帕米降低NT-proBNP 177 ng/L(P<0.001),改善整体纵向应变1.1%(P=0.001)。
临床怎么用
- 对于非梗阻性HCM患者,选择比索洛尔或维拉帕米时需考虑两者对运动能力、症状和生物标志物的不同影响。
- 比索洛尔可能降低运动耐量并升高NT-proBNP和左房容积指数,维拉帕米未显示这些不利变化。
- 维拉帕米可能改善心肌应变并降低NT-proBNP,但需结合患者个体情况权衡。
局限性
- 治疗期较短(2周稳态治疗),长期效果未知。
- 仅纳入具有至少一项疾病严重度标志的非梗阻性HCM患者,结果可能不适用于所有非梗阻性HCM患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized evidence supporting treatment with beta-blockers and calcium antagonists in nonobstructive hypertrophic cardiomyopathy (HCM) is absent. OBJECTIVES: The authors sought to analyze the effect of bisoprolol and verapamil treatment in nonobstructive HCM in a randomized, double-blinded, placebo-controlled triple-crossover trial. METHODS: Nonobstructive HCM patients with ≥1 marker of disease severity (NYHA functional class ≥II, N-terminal pro-B-type natriuretic peptide [NT-proBNP] >300 ng/L, or documented nonsustained ventricular tachycardia) were included. Each patient underwent 3 treatment periods with target doses of 7.5 mg bisoprolol, 360 mg verapamil, and placebo. Outcomes were evaluated after 2 weeks on steady-state treatment. The primary outcome was peak oxygen consumption (pVO2). In addition, exercise response, symptom, biomarker, structural, and myocardial changes were evaluated. RESULTS: Thirty-two patients (34% women) aged 54 ± 15 years were included. The pVO2 was 25.7 ± 8.7 mL/kg/min with bisoprolol, 28.2 ± 8.6 mL/kg/min with verapamil and 28.7 ± 8.7 mL/kg/min with placebo. The adjusted mean difference in pVO2 was -1.8 mL/kg/min (P = 0.013) bisoprolol vs verapamil, -2.5 mL/kg/min (P = 0.002) bisoprolol vs placebo and -0.7 mL/kg/min (P = 0.990) verapamil vs placebo. The peak heart rate was lower with bisoprolol (-37 beats/min; P < 0.001) and with verapamil (-17 beats/min; P < 0.001) compared with placebo. Neither bisoprolol nor verapamil changed the oxygen consumption at anaerobic threshold or the minute ventilation/CO2 production slope. Global longitudinal strain was improved by verapamil (-1.1%; P = 0.001) but unchanged by bisoprolol (-0.6%; P = 0.263) compared with placebo. Compared with placebo, treatment with bisoprolol reduced Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS; -6.6 points; P = 0.001), increased NT-proBNP (+165 ng/L; P = 0.006), increased left atrial volume index (LAVI; +13.0 mL/m2; P < 0.001), and increased tricuspid regurgitation (TR) pressure gradient (+4.3 mm Hg; P = 0.049). Treatment with verapamil did not change KCCQ-OSS (-2.3 points; P = 0.668), LAVI (+5.2 mL/m2; P = 0.194), or TR pressure gradients (+1.1 mm Hg; P = 1.000), but reduced NT-proBNP (-177 ng/L; P < 0.001) compared with placebo. NYHA functional classification was unchanged by treatments. CONCLUSIONS: In nonobstructive HCM, treatment with bisoprolol reduced pVO2, whereas it was unchanged with verapamil. There were a number of significant differences in exercise response, structural changes, myocardial function, symptoms, and biomarkers. This study provides new insights into the mechanisms of these drugs that might be taken into consideration in management of nonobstructive HCM.
引用
- Bjerregaard L, Dybro AM, Saaby L, et al. Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. J Am Coll Cardiol. 2026. PMID: 41778690. doi:10.1016/j.jacc.2025.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。